<DOC>
	<DOCNO>NCT00755937</DOCNO>
	<brief_summary>This registry multi-center , prospective , observational program gather analyze data subject Crohn 's disease treat Remicade® per approve product monograph Canada . In contrast control clinical trial , impose experimental intervention treatment Remicade® determine solely subject 's physician . Thus , data capture reported registry reflect `` real world '' approach treatment Crohn 's disease Remicade® .</brief_summary>
	<brief_title>Remicade® Crohn 's Disease Registry Across Canada ( Study P02793 )</brief_title>
	<detailed_description>Subjects select registry use non-probability sampling method .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patient give Patient Information Brochure ; AND , Patient never treat Remicade® ( patient naïve Remicade® time registration ) ; AND , Patient good candidate receive Remicade® per product monograph ; AND , Patient agree complete Patient Diary one week prior visit registry ; AND , Patient sign approve consent form . Per product monograph</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>